FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012175433> ?p ?o ?g. }

• W2012175433 endingPage "49" @default.
• W2012175433 startingPage "49" @default.
• W2012175433 abstract "Mineralocorticoid Receptor Antagonists (MRA) have proven their cardioprotective effects in individuals with chronic heart failure (CHF) by minimizing the cardiovascular damages caused by the excessive aldosterone production observed in those patients. Metabolic syndrome (MetS) that represents one of the major risk factors for CHF has been also reported to be associated with increased aldosterone levels and MR activation and may contribute in that way to the pathogenesis of HF. Thus, we hypothesized that targeting the MetS by the early antagonism of the MR may prevent or delay the subsequent transition to CHF in a rat model of HF associated or not with a MetS. MRA Eplerenone (100 mg/kg/day) or placebo was administrated to 1.5 month-old obese and lean Spontaneously Hypertensive Heart Failure male rats (SHHFcp/cp and SHHF+/+ respectively) for a period of 11 months. Animal metabolic and cardiac parameters were regularly monitored during the protocol. When compared to the SHHF+/+, MetS rats induces of mortality of 30% in SHHFcp/cp group that was completely prevented by the preventive treatment with Eplerenone. Indeed, SHHFcp/cp developed over time a massive obesity, dyslipidemia and insulin resistance. Echocardiograms showed an accelerated transition to cardiac dysfunction evidenced by left ventricular hypertrophy (LVH), a decreased relaxation and contractile properties of the myocardium as well as LV dilatation. MRA, prevented rats’ body weight gain (–10%), dyslipidemia (–50%) and enhanced adiponectinemia (+50%). Independently of a blood pressure decrease, cardiac parameters of Eple-SHHFcp/cp rats were preserved compared to SHHFcp/cp: LV diameter (9.9±0.14 vs 11.4±0.13 mm, respectively), LV mass (1760±72 vs 2195±73 mg), ejection fraction (70±1 vs 59±1%), isovolumic relaxation time (30±1 vs 22±1 ms) and E/A ratio (1.7±0.1 vs 3±0.3). Altogether, our data demonstrated that administration of eplerenone at the very early stages of MetS delayed their progression to CHF and prevented mortality. The beneficial cardioprotective effects were obtained via a mechanism independent of blood pressure lowering." @default.
• W2012175433 created "2016-06-24" @default.
• W2012175433 creator A5002930466 @default.
• W2012175433 creator A5008150469 @default.
• W2012175433 creator A5034724785 @default.
• W2012175433 creator A5036821495 @default.
• W2012175433 creator A5059892554 @default.
• W2012175433 creator A5060662126 @default.
• W2012175433 creator A5063949568 @default.
• W2012175433 creator A5067721540 @default.
• W2012175433 creator A5078709641 @default.
• W2012175433 creator A5090841548 @default.
• W2012175433 date "2014-04-01" @default.
• W2012175433 modified "2023-09-28" @default.
• W2012175433 title "0298: The early mineralocorticoid receptor antagonism mitigates the metabolic syndrome symptoms and transition to heart failure in the SHHF rat model" @default.
• W2012175433 doi "https://doi.org/10.1016/s1878-6480(14)71395-3" @default.
• W2012175433 hasPublicationYear "2014" @default.
• W2012175433 type Work @default.
• W2012175433 sameAs 2012175433 @default.
• W2012175433 citedByCount "1" @default.
• W2012175433 countsByYear W20121754332016 @default.
• W2012175433 crossrefType "journal-article" @default.
• W2012175433 hasAuthorship W2012175433A5002930466 @default.
• W2012175433 hasAuthorship W2012175433A5008150469 @default.
• W2012175433 hasAuthorship W2012175433A5034724785 @default.
• W2012175433 hasAuthorship W2012175433A5036821495 @default.
• W2012175433 hasAuthorship W2012175433A5059892554 @default.
• W2012175433 hasAuthorship W2012175433A5060662126 @default.
• W2012175433 hasAuthorship W2012175433A5063949568 @default.
• W2012175433 hasAuthorship W2012175433A5067721540 @default.
• W2012175433 hasAuthorship W2012175433A5078709641 @default.
• W2012175433 hasAuthorship W2012175433A5090841548 @default.
• W2012175433 hasBestOaLocation W20121754331 @default.
• W2012175433 hasConcept C126322002 @default.
• W2012175433 hasConcept C170493617 @default.
• W2012175433 hasConcept C189135053 @default.
• W2012175433 hasConcept C2776069600 @default.
• W2012175433 hasConcept C2777383412 @default.
• W2012175433 hasConcept C2778198053 @default.
• W2012175433 hasConcept C2778525890 @default.
• W2012175433 hasConcept C71924100 @default.
• W2012175433 hasConceptScore W2012175433C126322002 @default.
• W2012175433 hasConceptScore W2012175433C170493617 @default.
• W2012175433 hasConceptScore W2012175433C189135053 @default.
• W2012175433 hasConceptScore W2012175433C2776069600 @default.
• W2012175433 hasConceptScore W2012175433C2777383412 @default.
• W2012175433 hasConceptScore W2012175433C2778198053 @default.
• W2012175433 hasConceptScore W2012175433C2778525890 @default.
• W2012175433 hasConceptScore W2012175433C71924100 @default.
• W2012175433 hasLocation W20121754331 @default.
• W2012175433 hasOpenAccess W2012175433 @default.
• W2012175433 hasPrimaryLocation W20121754331 @default.
• W2012175433 hasRelatedWork W1512670312 @default.
• W2012175433 hasRelatedWork W1801018890 @default.
• W2012175433 hasRelatedWork W2023418293 @default.
• W2012175433 hasRelatedWork W2037408526 @default.
• W2012175433 hasRelatedWork W2069080293 @default.
• W2012175433 hasRelatedWork W2070491370 @default.
• W2012175433 hasRelatedWork W2164551443 @default.
• W2012175433 hasRelatedWork W2513383529 @default.
• W2012175433 hasRelatedWork W2866852080 @default.
• W2012175433 hasRelatedWork W4232426836 @default.
• W2012175433 hasVolume "6" @default.
• W2012175433 isParatext "false" @default.
• W2012175433 isRetracted "false" @default.
• W2012175433 magId "2012175433" @default.
• W2012175433 workType "article" @default.